Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mesengenic progenitor cells derived from human placenta.

Gerald G Wulf1, Volker Viereck, Bernhard Hemmerlein

  • 1Department of Hematology and Oncology, Georg August University Goettingen, 37075 Goettingen, Germany. gwulf@med.uni-goettingen.de

Tissue Engineering
|September 15, 2004
PubMed
Summary

Human placenta provides an abundant source of multipotent mesengenic progenitor cells. These cells, isolated using simple techniques, demonstrate differentiation potential for regenerative medicine applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Bone marrow transplantation·2026
Same author

Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study.

Leukemia·2026
Same author

Timing of donor lymphocyte infusion after relapse following allogeneic hematopoietic cell transplantation: a retrospective single-center analysis.

Annals of hematology·2026
Same author

Clonal Cytogenetic Evolution in Relapse of Myeloid Hematological Neoplasms After Allogeneic Stem Cell Transplantation.

Cancers·2026
Same author

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

Leukemia·2026
Same author

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Area of Science:

  • Regenerative Medicine
  • Cell Biology
  • Tissue Engineering

Background:

  • Mesenchymal progenitor cells are valuable for regenerative medicine.
  • Bone marrow is a traditional source, but alternatives are sought.

Purpose of the Study:

  • To investigate human term placenta as an alternative source of multipotent mesengenic progenitor cells.
  • To characterize these placenta-derived cells and assess their differentiation capacity.

Main Methods:

  • Harvesting mononuclear cells from human term placenta via dissection and proteinase digestion.
  • Culturing cells and characterizing the mesenchymal population by surface marker expression (CD9, CD29, CD73).
  • Assessing in vitro growth behavior and differentiation potential along multiple lineages.

Related Experiment Videos

Main Results:

  • High numbers of viable mononuclear cells were obtained from placenta.
  • A mesenchymal cell population with characteristic markers was successfully cultured.
  • Placenta-derived cells exhibited similar in vitro growth to bone marrow cells and showed multipotent differentiation (osteogenic, chondrogenic, adipogenic, myogenic).
  • Cells were confirmed to be of maternal origin after three passages.

Conclusions:

  • Human term placenta is an easily accessible and abundant source of multipotent mesengenic progenitor cells.
  • These cells hold significant promise for regenerative medicine applications.
  • Placental progenitor cells offer a viable alternative to bone marrow-derived cells.